Royal Bank Of Canada Acelrx Pharmaceuticals Inc Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.28 - $0.61 $1,120 - $2,440	-4,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.02 $1,960 - $4,080	4,000 New	4,000 $2,000
Q3 2021 Nov 15, 2021	SELL	$0.93 - $1.51 $20,513 - $33,307	-22,058 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.03 - $1.7 $22,719 - $37,498	22,058 New	22,058 $31,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.